NCT05283135CompletedPhase 2
High Dose Risankizumab for Psoriasis
Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 24 Oct 2025
Brief summary (registry, in English)
This pilot study explores higher than standard doses of risankizumab for plaque psoriasis, to see effects on resident memory T cells and skin clearance.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 3 Feb 2022
- Start date
- 1 Mar 2022
- Primary completion date
- 7 Aug 2023
- Lead sponsor
- Oregon Medical Research Center
- Diseases
- Psoriasis
- NCT number
- NCT05283135
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 20
- From 1 Mar 2022 to the primary completion date, 7 Aug 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of any concurrent illness, which in the opinion of the investigator, would place the patient at unnecessary safety risk during the trial or interfere with completion of the trial
- Treatment with topical medications for psoriasis in the past 2 weeks
- Treatment with oral medications for psoriasis in the past 4 weeks
- Any prior treatment with Risankizumab
- Treatment with biologic medications for psoriasis (other than Risankizumab) in the past 4 months
Other illness
- Active infection with HIV, hepatitis B virus, or hepatitis C virus
- Active infection with tuberculosis or untreated latent tuberculosis
- History of known active cancer, other than non-melanoma skin cancer or cervical carcinoma in situ, in the past 3 years
- History of drug or alcohol abuse in the past 6 months, as per investigator's assessment
- History of suicidal ideation or attempts in the past 6 months
Other
- Breastfeeding or pregnant women, or women who plan to become pregnant during study period
- Participation in any other clinical trial
- Phototherapy for psoriasis in the past 4 weeks
Who the study is looking for
- Subject has provided written consent
- Subject has the ability to comply with all study visits and procedures
- Subject is at least 18 years of age
- Subject has chronic stable plaque psoriasis for at least 6 months and with a severity of BSA greater than or equal to 10 and PASI greater than or equal to 12
- Female subjects of child-bearing potential must have a negative urine test at screening and baseline. Female subjects must be either postmenopausal, or permanently surgically sterile, or for women of child-bearing potential practicing at least one form of birth control
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oregon Medical Research Center Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.